The discovery that eliminating senescent cells can extend healthspan and delay age-related pathologies in mice has catalyzed intense research into compounds capable of selectively clearing these cells. These compounds, termed "senolytics," represent a novel approach to targeting aging—rather than attempting to slow aging processes, they aim to remove cells that have already undergone age-related changes.
Since the first senolytic compounds were identified in 2015, the field has rapidly expanded, with multiple compounds showing promise in preclinical studies and early-stage clinical trials beginning to test whether senolytic approaches will benefit human health. This article explores what senolytics are, the evidence supporting their potential, the current state of research, and important limitations and unknowns.
As discussed in our article on cellular senescence, senescent cells accumulate with age and contribute to tissue dysfunction through their senescence-associated secretory phenotype (SASP). While senescent cells represent only a small fraction of total cells in aged tissues—often less than 10-15%—their SASP secretions can have disproportionate effects on surrounding tissues.
The foundational evidence that eliminating senescent cells could be beneficial came from genetic studies in mice. In 2011, researchers led by Darren Baker and Jan van Deursen developed a transgenic mouse model (INK-ATTAC) that allowed selective elimination of p16INK4a-expressing senescent cells.
When senescent cells were cleared from naturally aging mice, the animals showed:
Subsequent studies using similar genetic approaches confirmed and extended these findings, establishing that senescent cell burden contributes to age-related dysfunction and that removing these cells can provide benefits.
While genetic elimination of senescent cells proved the concept, therapeutic application requires pharmacological approaches—compounds that can selectively induce death in senescent cells while sparing normal cells.
This selectivity is crucial. Senescent cells have several characteristics that distinguish them from normal cells, but none is entirely unique. Effective senolytics must exploit differences between senescent and normal cells to achieve sufficient selectivity.
Senescent cells are characterized by their resistance to apoptosis (programmed cell death). This resistance occurs through upregulation of pro-survival pathways and anti-apoptotic proteins, which allows senescent cells to persist despite being damaged.
Research has identified multiple anti-apoptotic pathways upregulated in senescent cells, including:
Different types of senescent cells may rely on different combinations of these pathways, which partially explains why different senolytics show cell-type specificity.
Senolytics work by inhibiting these anti-apoptotic pathways. By blocking the proteins that allow senescent cells to evade death, senolytics tip the balance toward apoptosis in senescent cells. Because normal cells don't rely as heavily on these particular survival pathways, they are relatively spared.
However, this selectivity is not absolute—most senolytics can affect normal cells at higher concentrations, which is why dosing and safety are critical considerations.
In 2015, researchers including James Kirkland and colleagues reported the identification of the first senolytic drugs: dasatinib (a tyrosine kinase inhibitor) and quercetin (a natural flavonoid).
The researchers used a computational approach, analyzing gene expression in senescent cells to identify pathways that might confer resistance to apoptosis. They then tested compounds targeting these pathways for senolytic activity in cell culture.
Interestingly, neither dasatinib nor quercetin alone showed strong senolytic activity across all senescent cell types, but the combination (D+Q) showed broad efficacy, suggesting they target complementary pathways.
Dasatinib: A multi-kinase inhibitor originally developed for cancer treatment, dasatinib inhibits several tyrosine kinases involved in cell survival signaling. It appears particularly effective against senescent human adipocyte progenitors and some other cell types.
Quercetin: A naturally occurring flavonoid found in many fruits and vegetables, quercetin inhibits various kinases including PI3K and serpines. It shows particular efficacy against senescent human endothelial cells and some other cell types.
The combination targets a broader range of senescent cell types than either compound alone.
Following their discovery, D+Q has been tested extensively in animal models:
Aged mice: D+Q treatment improved physical function, reduced inflammation, and extended healthspan in naturally aged mice. In some studies, even single or intermittent treatments produced sustained benefits.
Disease models: D+Q showed benefits in animal models of various conditions including:
Based on promising preclinical results, small clinical trials have begun testing D+Q in humans:
Idiopathic Pulmonary Fibrosis (2019): A small pilot study (14 participants) tested D+Q in patients with this fibrotic lung disease. The treatment was well-tolerated and showed improvements in some physical function measures, though the study was too small for definitive conclusions.
Diabetic Kidney Disease (2020): A small trial examined D+Q effects in diabetic kidney disease, finding the treatment was safe and showed trends toward reduced senescent cell markers in adipose tissue.
Frailty (ongoing): Several trials are testing D+Q in elderly individuals with frailty, examining effects on physical function, inflammation, and other outcomes.
All completed trials to date have been small (typically fewer than 20 participants) and primarily focused on safety and feasibility, with efficacy endpoints being exploratory. Larger trials are needed to determine clinical efficacy.
In 2018, researchers identified fisetin—another naturally occurring flavonoid found in strawberries, apples, and other fruits—as a senolytic compound.
Studies in aged mice found that fisetin treatment:
Notably, fisetin showed efficacy across a broader range of senescent cell types than D+Q in some assays, potentially making it useful as a single-agent senolytic.
Fisetin appears to work through multiple mechanisms including inhibition of PI3K/AKT pathways, modulation of autophagy, and effects on various kinases. Its senolytic activity likely reflects combined effects on multiple survival pathways.
Small pilot studies have begun testing fisetin in humans:
A 2019 pilot study in 11 women with frailty tested high-dose fisetin (20 mg/kg daily for 2 consecutive days, repeated monthly). The treatment appeared safe, and exploratory analyses suggested possible reductions in inflammatory markers, though the study was too small for definitive conclusions.
Additional trials in various conditions including osteoarthritis and cognitive decline are ongoing.
Research continues to identify additional senolytic compounds with different mechanisms and properties.
Originally developed as a cancer drug, navitoclax inhibits BCL-2 family proteins (BCL-2, BCL-xL, BCL-W) that prevent apoptosis. It shows potent senolytic activity in preclinical models.
Studies in mice have shown that navitoclax can eliminate senescent cells and improve various age-related pathologies. However, it causes thrombocytopenia (reduced platelet counts) in humans because platelets depend on BCL-xL for survival, limiting its use for chronic senescent cell clearance.
Researchers are working on modified versions that might retain senolytic activity while reducing platelet effects.
Compounds including digoxin, digitoxin, and ouabain show senolytic activity in some cell types. These drugs affect Na+/K+-ATPase and have been used medically for decades for heart conditions, potentially allowing faster clinical translation if senolytic applications prove valuable.
A natural compound from the long pepper plant, piperlongumine shows senolytic activity through mechanisms involving oxidative stress response pathways. Preclinical studies have shown efficacy in some models, though human data are lacking.
A novel approach uses compounds conjugated to galactose sugars. Senescent cells often overexpress β-galactosidase (used as a senescence marker). Galacto-conjugated prodrugs can be cleaved by β-galactosidase in senescent cells, releasing toxic compounds selectively in these cells.
This strategy could improve selectivity but remains in early research stages.
While senolytics aim to eliminate senescent cells, an alternative strategy called "senomorphics" targets the SASP without killing senescent cells.
Since much of senescent cells' detrimental effects come from their secretory phenotype, suppressing SASP secretion might provide benefits while avoiding potential risks of cell elimination.
Rapamycin: The mTOR inhibitor rapamycin suppresses some SASP factors without killing senescent cells. Studies in mice have shown it can improve various age-related parameters.
JAK inhibitors: Inhibitors of JAK (Janus kinase) signaling can reduce SASP secretion. Research in mice has shown benefits in some models of age-related dysfunction.
Glucocorticoids: These anti-inflammatory drugs can suppress some SASP factors, though with significant side effects that limit chronic use.
Both approaches have potential advantages and limitations:
Senolytics:
Senomorphics:
Some researchers propose that combining approaches or using them sequentially might prove most effective.
Despite exciting preclinical findings, important questions and challenges remain regarding senolytic approaches.
Selectivity limitations: No senolytic shows perfect selectivity for senescent cells. At higher doses or with chronic use, effects on normal cells could occur.
Beneficial senescence: Senescence serves important functions in wound healing and tumor suppression. Excessive or poorly timed senescent cell clearance could impair these beneficial processes.
Tissue regeneration: Some concern exists about whether clearing senescent cells might impair tissue regeneration, as senescent cells can secrete factors promoting healing in certain contexts.
Unknown long-term effects: Chronic or repeated senolytic treatment might have unforeseen effects that haven't emerged in short-term studies.
Cell-type specificity: Different senolytics show activity against different senescent cell types. No single compound eliminates all senescent cells, raising questions about optimal compound selection or combinations.
Tissue penetration: Whether senolytics reach all tissues where senescent cells accumulate, particularly brain and other protected sites, remains uncertain.
Dosing and timing: Optimal dosing regimens—continuous vs. intermittent, dose levels, treatment duration—remain to be determined.
Mouse to human translation: As with all aging interventions, effects in mice may not translate to humans. Mice have different lifespans, metabolic rates, and potentially different senescent cell biology.
Measuring outcomes: In animal studies, researchers can examine tissues directly and follow animals throughout their lives. In humans, measuring senescent cell burden and functional outcomes is more challenging.
Clinical trial design: Designing trials to test effects on aging or age-related decline faces methodological challenges. Which outcomes to measure, over what timeframe, in which populations, remain active questions.
Despite rapid progress, fundamental questions remain:
The field of senolytics has advanced remarkably quickly from initial concept to clinical testing, but remains in early stages.
As of 2026, numerous clinical trials are testing senolytics in various conditions:
Most trials remain small and early-stage, focused on safety, tolerability, and preliminary efficacy signals. Larger phase 2 and phase 3 trials will be needed to establish clinical efficacy.
Key research directions include:
While preclinical results are encouraging, translating these findings to proven human therapies typically takes many years. Realistic expectations should include:
Senolytics represent a novel approach to addressing age-related decline—targeting not aging processes per se, but the accumulated products of those processes. The proof-of-concept that eliminating senescent cells can improve healthspan in mice has motivated rapid development of compounds capable of selectively clearing these cells.
Multiple senolytic compounds have been identified, each with different mechanisms, cell-type specificities, and properties. Preclinical studies have shown impressive benefits across diverse models of aging and age-related disease, supporting the hypothesis that senescent cell burden contributes to age-related pathology.
However, translation to humans remains in early stages. While small clinical trials have shown that senolytics are generally safe in the short term and can reduce some senescence markers, whether they will produce meaningful improvements in human healthspan or delay age-related diseases requires larger, longer-term trials.
Important questions remain about safety, optimal compounds and combinations, dosing strategies, and which populations might benefit most. The field continues to evolve rapidly, with new compounds being identified and clinical evidence accumulating.
Understanding senolytics provides insight into how targeting specific cellular pathways might address aging-related dysfunction. As research progresses from preclinical studies through clinical trials, the coming years will reveal whether this promising approach will translate into meaningful interventions for human aging and age-related disease.